Chester County News and Community Website
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced a significant advancement in its cardiovascular portfolio with the issuance of a new patent for its drug istaroxime in Japan. The …
Windtree Therapeutics Secures Patent for Heart Failure Treatment in Japan Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the publication of its SEISMiC Phase 2b trial design by the European Society of Cardiology Heart Failure. The trial is exploring …
Windtree Therapeutics Publishes SEISMiC Phase 2b Trial Design for Cardiac Treatment Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced encouraging topline results from its Phase 2b SEISMiC Extension Study investigating istaroxime in patients experiencing early cardiogenic shock due to heart …
Windtree Therapeutics Announces Positive Results in Heart Failure Study Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) is set to host a virtual Investor Day Presentation on October 1 at 3 pm ET, where it will unveil promising new results …
Windtree Therapeutics Announces Key Investor Day for Groundbreaking Heart Treatment Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has reported promising outcomes from its Phase 2b SEISMiC Extension Study, showcasing the potential of istaroxime in managing early cardiogenic shock caused by …
Windtree Therapeutics Announces Promising Results for Heart Failure Drug Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the successful completion of patient enrollment in its SEISMiC Extension Phase 2b study. This research focuses on istaroxime, a promising therapy …
Windtree Therapeutics Advances Heart Failure Treatment with SEISMiC Extension Study Completion Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently announced its financial results for the second quarter ending June 30, 2024, along with significant business updates. The company has made …
Windtree Therapeutics Reports Second-Quarter Financial Results and Key Business Updates Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has made significant changes to its board of directors, effective August 13, 2024. The company has appointed Saundra Pelletier and Jed Latkin …
Windtree Therapeutics Announces New Board Appointments Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotech firm based in Bucks County, has shared significant updates on its novel heart failure therapy, istaroxime. This therapy aims to …
Windtree Therapeutics Advances Heart Failure Treatment in New Clinical Trials Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a clinical-stage biopharmaceutical company, has successfully navigated back to compliance with Nasdaq’s minimum bid price requirement, a crucial step for maintaining its …
Windtree Therapeutics Regains Nasdaq Compliance with Minimum Bid Price Requirement Read More